-
Vinorelbine: a vinca alkaloid chemotherapy agent
Vinorelbine (also named Navelbine) is an anti-tumor semi-synthetic vinca-alkaloid compound discovered in France and mainly used in breast cancer and non-small cell lung cancer. The original vinca-alkaloids were derived from the dried leaves of the Madagascan periwinkle (vinca rosea).
Author:Nicholas Pavlidis
Date of publication:Read more03 June 2024
-
Adriamycin, a mainstay in drug cancer treatment
Adriamycin is an anti-tumor antibiotic discovered in Italy, which has been and is still being used in a wide variety of tumors. The laboratory and the initial clinical studies leading to the demonstration of its usefulness were carried out in Italy.
Author:Silvio Monfardini
Date of publication:Read more17 May 2024
-
Back to the future? Temozolomide for brain tumours
Brain tumours are among the cancers with the worst outlook and are hard to treat owing to factors such as inoperable locations in the brain and the difficulty of developing drugs that can cross the blood-brain barrier.
Author:Anna Wagstaff
Date of publication:Read more17 May 2024
-
Platinum chemotherapy: a mainstay in drug treatment - Cisplatin
Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.
Author:Rachel Brazil
Date of publication:Read more14 September 2022
-
Platinum chemotherapy: a mainstay in drug treatment - Oxaliplatin
Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.
Author:Rachel Brazil
Date of publication:Read more06 September 2022
-
Platinum chemotherapy: a mainstay in drug treatment - Carboplatin
Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.
Author:Rachel Brazil
Date of publication:Read more21 July 2022